Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...

We have a specific approach with which we have reduced the question of Eisai's value to a question of the success of the Lenvima and Leqembi products, which for reasons we explained in our first ...

Eisai has lowered the sales forecast for its Alzheimer’s drug Leqembi (lecanemab), primarily citing delays in revenue in the US. The Japanese pharma expects its lead product co-developed with ...

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...

The EMA sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.

(RTTNews) - Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European ...

BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that CareMed, a ...